A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

PURPOSE: A combination kit containing pinitol and a drug for preventing or treating diabetes is provided to reduce side effects and to quickly treat diabetes. CONSTITUTION: A combination kit of a component for preventing or treating diabetes contains pinitol as a first ingredient and a drug of biguanide meglitinide or sulfonylurea as a second ingredient. The biguanide is metformin. The meglitinide is repaplinide or nateglinide. The sulfonylurea is carbutamide acetohexamide chlorpropamide tolbuta...

595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

A polymeric construct is disclosed. The construct comprises a polysaccharide polymer having a selected medicament associated therewith. The medicament th us present is provided in a slow release form. lt;SDOCL LA=ENgt; 18 We Claim 1. A polymeric construct comprising a polysaccharide polymer having a selected medicament entrapped therewithin. 2. The construct as defined in claim 1 wherein said polymer is selected from the group consisting of alginic acid or a pharmaceutically acceptable salt ther...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2...

1. A use of an insulin sensitiser an insulin secretagogue and a biguanide antihyperglycaemic agent as a pharmaceutically acceptable carrier therefor for use as an active therapeutic substance for treating diabetes mellitus and conditions associated with diabetes mellitus wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound I) which comprises the administration of 2 to 12 mg of said Compound. 2. The use according to claim 1 wherein ...

PROBLEM TO BE SOLVED: To allow recovery of lowered functional of motor and sensory nerves in patients suffering from diabetic neuropathy by using beraprost in combination with a medicine for diabetes. SOLUTION: Treatment of the diabetic neuropathy especially one accompanied by lowering in nervous conduction speed is performed by using (A) beraprost in combination with (B) a medicine for diabetes. As the component B an insulin-containing preparation or a medicine for diabetes for oral use specifi...

PURPOSE: To obtain a medicine preparation for treating true diabetes and related conditions comprising a 2-(phenoxypropanolamino)ethoxyphenoxy acetic acid derivative and sulfonylurea.CONSTITUTION: This medicine comprises (A) a compound of the formula (R is OH or 2-ethodxyethylamino) known as a heat generating agent and useful for treating obesity related to diabetes or its pharmacologically permissible salt preferably (S)-4-[2-(2-hydroxy-3-phenoxypropyIamino)ethoxy]-N-(2- methoxyamino)phenoxyace...